Apex Biotechnology (TPE:1733) Research & Development: NT$149 Mil (TTM As of Dec. 2025)


TPE:1733 Apex Biotechnology Corp TPE:1733
81 GF Score
Price NT$29.90
GF Value NT$30.08
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Apex Biotechnology Research & Development?

Apex Biotechnology TPE:1733 -0.17% 81 Research & Development is NT$149 Mil as of Dec. 2025. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Apex Biotechnology's Research & Development for the three months ended in Dec. 2025 was NT$36 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$149 Mil.

Apex Biotechnology  (TPE:1733) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Apex Biotechnology Research & Development Related Terms

Apex Biotechnology Research & Development Historical Data

* Premium members only.

The historical data trend for Apex Biotechnology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apex Biotechnology Research & Development Chart

Apex Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 153.29 165.45 163.33 161.52 149.37

Apex Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.31 40.44 36.96 35.94 36.03
TPE:1733
81GF Score
Apex Biotechnology Corp TPE:1733
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apex Biotechnology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$149 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$149 Mil mean?
Apex Biotechnology (TPE:1733) has a Research & Development of NT$149 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Apex Biotechnology and its competitors.
Is Apex Biotechnology's Research & Development too high?
Apex Biotechnology's current Research & Development is NT$149 Mil. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Research & Development compare to VRTX and REGN?
Apex Biotechnology's Research & Development of NT$149 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Apex Biotechnology and its competitors. Apex Biotechnology's current Research & Development is NT$149 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Research & Development is NT$149 Mil. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Research & Development is NT$149 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Apex Biotechnology (TPE:1733) Overvalued in 2026?

Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued. The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08. GuruFocus considers Apex Biotechnology to be Fairly Valued.

Key valuation signals for TPE:1733:

  • Research & Development: NT$149 Mil
  • GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
  • GF Score™: 81/100 with 2 warning signs

No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Apex Biotechnology Business Description

Address Li-Hsin 5th Road, No. 7, Hsinchu Science Park, Hsinchu, TWN, 30078
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score

Get the complete analysis for TPE:1733

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$29.90
Price
NT$30.08
GF Value